Intravenous Labetalol Versus Hydralazine in Preeclampsia

Phase 2RecruitingNCT06360601

Tanta University40 enrolled

Overview

We study the effect of intravenous labetalol versus hydralazine in sever preeclampsia patients on cerebral blood flow and neurological outcome

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

Conditions

Preeclampsia Severe

Interventions

Labetalol InjectionDRUG

Labetalol intravenous infusion 20ml/hr

HydrALAZINE InjectionDRUG

Hydralazine intravenous infusion 5mg/hr

Eligibility

Sex: FEMALEMin age: 25 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient with clinical diagnosis of sever preeclampsia Exclusion Criteria: Patient with history of previous intracranial lesion Patient with history of heart disease/allergy to drug Patient with history of arrhythmia/anticoagulation Any craniotemporal lesion \-

Locations (1)

Tanta Univeristy hospitals

Tanta, Egypt

RECRUITING

Outcomes

Primary Outcomes

Cerebral blood flow

Mean cerebral blood flow and cerebral perfusion pressure

Time frame: Pre intervention-after one hour of intervention

Central Contacts

shimaa zahraa

CONTACT

201550273707 Meikamal89@outlook.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.